Amendment No. 1 to License Agreement by and between the Registrant and Sanofi, dated April 15, 2022

Exhibit 10.1

CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

EXECUTION VERSION

AMENDMENT NO. 1 TO LICENSE AGREEMENT

This Amendment No.1 (the “Amendment”) to the License Agreement effective as of March 12, 2021 (the “Agreement”) is made and entered into as of April 15th, 2022 (the “Amendment Effective Date”) by and between Sanofi, a French corporation located at 54, rue La Boétie, 75008 Paris, France (“Sanofi”) and Global Blood Therapeutics, Inc., a Delaware corporation located at 181 Oyster Point Boulevard, South San Francisco, CA, 94080 USA (“Licensee”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.

WHEREAS, the Parties desire to amend the Agreement to update the lists of the Licensed Compounds, the Transferred Materials and the Licensed Know-How.

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and adequacy of which are hereby aknowledged, the Parties hereto, intending to be legally bound, hereby agree as follows:

This Amendment is executed by the authorized representatives of the Parties as of the date of first written above.

1

EXHIBIT A

Licensed Compounds

Target 1 – Licensed Compounds

2

EXHIBIT B

Transferred Materials

Target 1 – Transferred Materials

Target 2 – Transferred Materials

3

4

EXHIBIT C

Licensed Know-How

5